Robinhood Markets, Inc. to Announce Fourth Quarter and Full Year 2023 Results on February 13, 2024
MENLO PARK, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — Today, Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) announced that it will […]
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 […]
Great Lakes Provides Update on Empire Wind I and II Contracts
HOUSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (NASDAQ: GLDD), […]
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately […]
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical […]
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry’s First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic […]
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Plans to advance diverse pipeline of programs in oncology and metabolic diseases Anticipates key proof-of-concept readouts for TERN-701 (CML) and […]
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing […]
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical […]
QIAGEN verstärkt Investitionen in sein Bioinformatik-Geschäft QIAGEN Digital Insights
Investitionen in QIAGEN Digital Insights (QDI) stärken führende Branchenposition durch profitable Expansion in neue Regionen, Marktsegmente und erweiterte Produktangebote // […]
